Appointment of Joint Corporate Broker

Aptamer Group PLC

20 August 2026

 

20 August 2026

Aptamer Group plc

("Aptamer", the "Company" or the "Group")

Appointment of Joint Corporate Broker

Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic Optimer® binders, is pleased to announce the appointment of Cavendish Capital Markets Limited ("Cavendish") as Joint Corporate Broker to the Company with immediate effect.

Cavendish will work alongside Turner Pope Investments (TPI) Limited, which will continue to act as Joint Corporate Broker.

As Aptamer continues to advance its therapeutic programmes, the appointment is intended to broaden research coverage and institutional engagement, drawing on Cavendish's specialist healthcare expertise and established relationships within the life sciences sector. 

-      Ends -

For further information, please contact: 

Aptamer Group plc   Dr Arron Tolley, Chief Executive Officer	[phone]
SPARK Advisory Partners Limited - Nominated Adviser     Andrew Emmott / Dillon Wall	[phone]
Cavendish Capital Markets Limited - Joint Broker Geoff Nash / Seamus Fricker / Joe Smith	[phone]
Turner Pope Investments (TPI) Limited - Joint Broker     Andrew Thacker / Guy McDougall	[phone]
Northstar Communications Limited - Investor Relations Sarah Hollins	[phone]

 About Aptamer Group

Aptamer Group plc (AIM: APTA) develops Optimer® binders, next-generation synthetic alternatives to antibodies that offer high specificity, improved stability, lower cost and access to targets beyond the reach of conventional modalities.

The Group operates a dual-revenue model, generating near-term revenues through fee-for-service discovery programmes while building a portfolio of proprietary therapeutic assets designed to create long-term value through licensing, royalties and supply agreements.

Aptamer is strategically focused on two of the most significant challenges in modern drug development: targeting "undruggable" proteins and enabling delivery of therapeutics to tissues beyond the liver. Its proprietary Optimer® platform, supported by more than 15 years of discovery data and an expanding AI-enabled discovery engine, is designed to accelerate the identification of high-quality binders against challenging biological targets.

The Group's internal pipeline includes targeted delivery vehicles for oligonucleotide therapeutics and radioligand therapy programmes, with upcoming in vivo studies expected to support future partnering and licensing opportunities.

Founded in 2008 and headquartered in York, UK, Aptamer works with many of the world's leading pharmaceutical companies, combining platform expertise, proprietary data and therapeutic innovation to create shareholder value.

 

END